Literature DB >> 6967881

Isotype-specific human B lymphocytes that produce immunoglobulin E in vitro when stimulated by pokeweed mitogen.

A Saxon, M Kaplan, R H Stevens.   

Abstract

Normal human peripheral blood lymphocytes can be stimulated by PWM and T cells to produce IgE in vitro. Between 4% and 10% of circulating B lymphocytes were found to bear noncytophilic membrane IgE. In contrast, limiting diluton analysis of active B cell precursor frequency revealed that only about 1 in 50,000 B cells was responsible for the synthesis of IgE in vitro. Variation inthe precursor frequency was primarily responsible for differences in the amount of IgE produced in vitro by different individuals while the amount of IgE produced per precursor cell was relatively constant. B lymphocytes with surface IgM, IgG, or IgE were depleted. Depletion of IgE-bearing cells decreased IgE production 70% to 83% while IgM-bearing-cell removal lowered IgE synthesis by 59% to 72%. Dual removal of IgM- and IgE-bearing cells did not give an additive effect. IgE- and IgM-positive B cells showed enhanced IgE synthesis of 327% and 182%, respectively. The consequences of crosslinking different surface isotypes on subsequent IgE production were also assessed. Anti-epsilon treatment inhibited IgE production up to 68% while anti-mu treatment decreased it by up to 38%. Thus only a very limited subset of B lymphocytes is responsible for PWM and T cell-dependent IgE synthesis in vitro and those cells probably bear both surface IgE and IgM.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6967881     DOI: 10.1016/0091-6749(80)90045-7

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  10 in total

1.  Comparison of IgE expression at the mRNA and protein levels in vitro.

Authors:  K J Turner; J Creany; R J Coelen; K J Cameron; B J Holt; M W Beilharz
Journal:  Immunology       Date:  1991-12       Impact factor: 7.397

Review 2.  Genetic control of IgE immune response.

Authors:  S Matsushita; T Sasazuki
Journal:  Clin Rev Allergy       Date:  1989

3.  In vitro synthesis of IgE by human peripheral blood leucocytes. III. Release of pre-formed antibody.

Authors:  K J Turner; P G Holt; B J Holt; K J Cameron
Journal:  Clin Exp Immunol       Date:  1983-02       Impact factor: 4.330

4.  IgE production in vitro by peripheral blood mononuclear cells of patients with parasitic helminth infections.

Authors:  T B Nutman; R Hussain; E A Ottesen
Journal:  Clin Exp Immunol       Date:  1984-10       Impact factor: 4.330

5.  Role of T gamma cells in the in vitro IgE response after antigenic stimulation.

Authors:  C Vela; R Garcia; L Tricas; C Platas; C Lahoz
Journal:  Clin Exp Immunol       Date:  1981-12       Impact factor: 4.330

6.  In vitro production of IgE by human peripheral blood mononuclear cells. IV. Modulation by allergen of the spontaneous IgE antibody biosynthesis.

Authors:  S Romagnani; E Maggi; G F Del Prete; F Almerigogna; R Biagiotti; M G Giudizi; M Ricci
Journal:  Clin Exp Immunol       Date:  1982-07       Impact factor: 4.330

7.  Regulation of immunoglobulin E antibody synthesis in man by antiidiotypic antibodies.

Authors:  R S Geha; M Comunale
Journal:  J Clin Invest       Date:  1983-01       Impact factor: 14.808

8.  In vitro stimulation of IgE production at a single precursor level by human alloreactive T helper clones.

Authors:  A Lanzavecchia; B Parodi
Journal:  Clin Exp Immunol       Date:  1984-01       Impact factor: 4.330

9.  Selective enhancement of human IgE production in vitro by synergy of pokeweed mitogen and mercuric chloride.

Authors:  H Kimata; K Shinomiya; H Mikawa
Journal:  Clin Exp Immunol       Date:  1983-07       Impact factor: 4.330

10.  In vitro production of IgE by human peripheral blood mononuclear cells. III. Demonstration of a circulating IgE-bearing cell involved in the spontaneous IgE biosynthesis.

Authors:  S Romagnani; G Damiani; M G Giudizi; R Biagiotti; F Almerigogna; G F Delprete; E Maggi; A Bargellesi; M Ricci
Journal:  Clin Exp Immunol       Date:  1982-07       Impact factor: 4.330

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.